tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Luchini, 62 are a HOLD (40.26%), 92 are a BUY (59.74%).
Analyst Matthew Luchini, carries an average stock price target met ratio of 45.21% that have a potential upside of 20.76% achieved within 297 days. Previously, Matthew Luchini worked at BMO.
Matthew Luchini’s has documented 295 price targets and ratings displayed on 31 stocks. The coverage was on Healthcare, Industrials, Energy, Technology sectors.
Most recent stock forecast was given on REPL, Replimune Group at 18-Mar-2022.
Analyst best performing recommendations are on ONCE (SPARK THERAPEUTICS).
The best stock recommendation documented was for ONCE (SPARK THERAPEUTICS) at 8/6/2018. The price target of $60 was fulfilled within 1 day with a profit of $17.61 (22.69%) receiving and performance score of 226.9.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Feb-2015
3 years 10 months 19 days ago
(25-Oct-2022)
0/10 (0%)
$13.99 (348.88%)
Hold Since 25-Oct-2022
$0.4
$0.01 (2.56%)
3 years 10 months 19 days ago
(25-Oct-2022)
1/1 (100%)
$0.01 (2.56%)
2
Buy Since 09-Feb-2017
$9
3 years 10 months 20 days ago
(24-Oct-2022)
1/3 (33.33%)
$7.17 (391.80%)
104
$0.34
$-0.05 (-12.82%)
3 years 10 months 20 days ago
(24-Oct-2022)
0/5 (0%)
$-0.05 (-12.82%)
Buy Since 11-Nov-2020
3 years 11 months 15 days ago
(29-Sep-2022)
0/2 (0%)
$6.72 (157.01%)
